Belite Bio, Inc BLTE

Wall Street wrapped a turbulent week with a wave of upgrades and downgrades hitting energy giants, homebuilders, and tech names just ahead of the Labor Day weekend. Find out which stocks analysts are rushing to buy and which ones just lost their support.

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in four upcoming investor conferences. Details of the presentations are as follows: Wells Fargo 21st Annual Healthcare Conference (Boston, MA) September 8, 2026, at 8:45 am E

SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a Virtual Commercial Day on Wednesday, September 2, 2026, from 8:00 – 9:30 a.m. ET. Belite Bio’s management team will be joined by leading experts in ophthalmology and people living with Star

Belite Bio (BLTE) is back in focus after the FDA accepted its New Drug Application for tinlarebant with Priority Review, a key regulatory step that accompanies the company’s latest quarterly earnings report. See our latest analysis for Belite Bio. Belite Bio’s share price has been volatile around these updates, with a one day share price return down 7.07% but a 30 day share price return of 11.25% and a one year total shareholder return of 149.56%. This suggests momentum has been strong over a...

Belite Bio stock has delivered a very large 431.2% return over the past three years, while its valuation checks and current market multiples point to a less straightforward picture of how much is already priced in. Belite Bio has returned 431.2% over three years, which sets a high bar for any further upside to be justified by the fundamentals. Regulatory progress for tinlarebant, including the FDA Priority Review for Stargardt Disease Type 1, can support expectations for future cash...

Belite Bio Inc (BLTE) reports robust progress with FDA NDA acceptance and a $780 million cash runway, despite widening losses and delayed GA trial interim analysis.

U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); Prescription Drug User Fee Act (PDUFA) target action date of February 12, 2027Company presented additional positive secondary endpoint data from the Phase 3 DRAGON trial of tinlarebant at the American Society of Retina Specialists (ASRS) Annual Meeting with quantitative autofluorescence (qAF) showing a marked divergence betwee

Prescription Drug User Fee Act target action date is February 12, 2027If approved, tinlarebant would be the first-ever approved treatment for Stargardt Disease Type 1 SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the U.S. Food and Drug Administration